Navigation Links
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Date:5/21/2008

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the initiation of the REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) Phase 2 clinical trial of voreloxin (also known as SNS-595), the company's lead anti-cancer therapeutic. The REVEAL-1 trial is being conducted in previously untreated elderly patients with acute myeloid leukemia (AML) who are unlikely to benefit from standard induction therapy. The first patient was enrolled and treated at the Indiana University Melvin and Bren Simon Cancer Center under the care of Larry D. Cripe, M.D., Associate Professor, Department of Medicine, Division of Hematology/Oncology at the Indiana University School of Medicine.

The primary objective of the REVEAL-1 trial is to evaluate voreloxin's anti-leukemic activity as a single agent, measured as either complete remission (CR) or complete remission without full platelet recovery (CRp). The study will also measure the duration of these responses. In order to qualify for the trial, patients must be at least age 60 with previously untreated AML and satisfy at least one of the following factors: poor performance status (PS 2); intermediate or unfavorable cytogenetics; prior antecedent hematologic disorder; or age greater than or equal to 70 years. Patients enrolled in the trial will receive three weekly doses of 72 mg/m2 of voreloxin in a treatment cycle. Approximately 55 patients will be enrolled in the open-label, multi-center REVEAL-1 trial.

"We are pleased to move our voreloxin program forward in AML with this Phase 2 trial. Based on the clinical activity and tolerability profiles observed in our Phase 1 trial of voreloxin in relapsed/refractory AML patients
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
3. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
4. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it ... $3.3 million at a price of $0.30 per unit. ... investor. Each unit consists of one common share and ... Each whole warrant entitles the holder to acquire one ... period of five years from closing.  ...
(Date:11/26/2014)... 26, 2014 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... of previously announced concurrent financing transactions resulting in ... estimated offering expenses, Lexicon anticipates net proceeds of ... consisted of: , a public offering ... a registration statement that has been declared effective ...
(Date:11/26/2014)... , November 26, 2014 Investor-Edge has ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ... Johnson (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... can be accessed at: http://investor-edge.com/register . On ... up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... , Increased vaccination ... gaps remain, others must join effort , DAVOS, Switzerland ... announced today that their foundation will commit $10 billion ... deliver vaccines for the world,s poorest countries. , (Photo: ...
... , , REDWOOD CITY, Calif. ... today announced financial results for its fiscal second quarter and six months ... call at 4:30 p.m. Eastern Time to discuss the financial ... quarter, as we continued to transition the sales model for our cardiac ...
Cached Medicine Technology:Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 2Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 3Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 4Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 5Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 2Cardica Announces Fiscal 2010 Second Quarter Financial Results 3Cardica Announces Fiscal 2010 Second Quarter Financial Results 4Cardica Announces Fiscal 2010 Second Quarter Financial Results 5Cardica Announces Fiscal 2010 Second Quarter Financial Results 6Cardica Announces Fiscal 2010 Second Quarter Financial Results 7Cardica Announces Fiscal 2010 Second Quarter Financial Results 8Cardica Announces Fiscal 2010 Second Quarter Financial Results 9
(Date:11/28/2014)... Dr. Diane Walder, one of South Florida’s top cosmetic ... called Ultrashape that is designed to help her patients reduce ... weeks. Ultrashape has been praised by patients as being permanent, ... to other types of external fat reduction. , “If you ... , According to Dr. Walder, Ultrashape works by targeting ...
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5
... - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Mellow ... that its clinical trial is currently being processed. The company ... days). The company expects the manufacturing license will be released ... to as "swine flu" early on) is a new influenza ...
... Hospitals, Physicians Work Together to Cut Costs, Improve ... 18 Twelve New Jersey hospitals and their participating physicians have ... incentive method that aims to reduce healthcare costs while improving quality ... could serve as a basis to overhaul government payment for Medicare ...
... , , LOS ANGELES, Aug. ... El Cancer (PADRES), a non-profit organization committed to improving the quality ... celebrate its ninth annual fund-raising gala, " EL SUENO DE ESPERANZA ... pay tribute to PADRES, extraordinary children and families, while at the ...
... speed, report shows , TUESDAY, Aug. 18 (HealthDay News) ... viral infection norovirus from a novel source: a tobacco ... tobacco plant using a bioengineered plant virus. , This ... ways to bring vaccines to the public quickly, especially ...
... PHILADELPHIA, Aug. 18 EwingCole, a nationally ... more than 320 professionals, today announced that it will ... Philadelphia, a 40-person firm with a robust portfolio of ... to take effect by September 1, 2009, will create ...
... , , , AUSTIN, ... a full-service pet travel company providing worldwide door-to-door pet trans ... pet health resource, P e tMD , to ... , The strategic affiliation will allow guests of PetMD to ...
Cached Medicine News:Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 2Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 2Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 3Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 4Health News:'Cruise Ship Virus' Vaccine Stems From Tobacco 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 2Health News:EwingCole, RDLA Join Together, Creating Architecture/Engineering Firm With Largest Healthcare Focus in the Delaware Valley 3Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 3
... The ABI PRISM 310 Genetic Analyzer ... for a wide range of sequencing and ... for academic and forensic labs who incorporate ... Genetic Analyzer -- the ideal alternative to ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: